GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Amazon Prime Air Cargo Plane Crash Kills Five at Miami Airport 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Anthropic IPO Marketing Expected to Start in Mid-October 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Add as a preferred source on Google
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
